Osteopetrosis Clinical Trial
Official title:
Clinical Assessment of Patients With High Bone Mass Due to Mutation in Low Density Lipoprotein l Receptor 5
Verified date | August 2010 |
Source | Odense University Hospital |
Contact | n/a |
Is FDA regulated | No |
Health authority | Denmark: Danish Dataprotection Agency |
Study type | Observational |
The aim of the study is to describe patients with a high bone mass phenotype due to a mutation in the low density lipoprotein l receptor 5 gene (LRP5) and compare them with age and sex matched controls. Moreover, bone density and microarchitecture as well as markers of bone metabolism are evaluated
Status | Completed |
Enrollment | 38 |
Est. completion date | June 2010 |
Est. primary completion date | April 2010 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Both |
Age group | 8 Years and older |
Eligibility |
Inclusion Criteria: - Lrp5 mutation/ADOI Exclusion Criteria: - Pregnancy |
Observational Model: Case Control, Time Perspective: Cross-Sectional
Country | Name | City | State |
---|---|---|---|
Denmark | Odense University Hospital, Osteoporosis Clinic | Odense |
Lead Sponsor | Collaborator |
---|---|
Odense University Hospital |
Denmark,
Frost M, Andersen TE, Yadav V, Brixen K, Karsenty G, Kassem M. Patients with high-bone-mass phenotype owing to Lrp5-T253I mutation have low plasma levels of serotonin. J Bone Miner Res. 2010 Mar;25(3):673-5. doi: 10.1002/jbmr.44. Erratum in: J Bone Miner — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Bone microarchitecture as assessed by high resolution quantitative computed tomography (HR-pQCT) | HR-pQCT is used to evaluate bone microarchitecture, i.e. bone trabeculae, cortical thickness and trabecular number. Aim is to test if the microarchitecture of these patients are different that observed in normal controls | 12 weeks | No |
Secondary | Changes in bone turnover markers | Markers of bone resorption and formation are investigated. | 12 weeks | No |
Secondary | Bone mineral density | DXA is used to evaluate bone mineral density at total hip, spine, whole body and forearm. | 12 weeks | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT01087398 -
Hematopoietic Stem Cell Transplantation for Malignant Infantile Osteopetrosis
|
Phase 2/Phase 3 | |
Terminated |
NCT00638820 -
Reduced Intensity AlloTransplant For Osteopetrosis
|
Phase 2 | |
Completed |
NCT00004402 -
Phase III Randomized Study of Interferon Gamma in Children With Severe, Congenital Osteopetrosis
|
Phase 3 | |
Recruiting |
NCT01019876 -
Risk-Adapted Allogeneic Stem Cell Transplantation For Mixed Donor Chimerism In Patients With Non-Malignant Diseases
|
Phase 2/Phase 3 | |
Terminated |
NCT00145587 -
Stem Cell Transplantation for Children Affected With Osteopetrosis
|
N/A | |
Completed |
NCT00043329 -
Post Marketing Surveillance Study of Actimmune in Patients With Severe, Malignant Osteopetrosis
|
Phase 4 | |
Recruiting |
NCT03333200 -
Longitudinal Study of Neurodegenerative Disorders
|
||
Completed |
NCT02666768 -
ACTIMMUNE in Intermediate Osteopetrosis
|
Phase 2 | |
Terminated |
NCT00145886 -
rhPTH Therapy for Low Turnover Bone Fragility
|
Phase 1 | |
Terminated |
NCT00968864 -
T-cell Depleted Alternative Donor Transplantation
|
Phase 2 | |
Completed |
NCT00730314 -
Unrelated Hematopoietic Stem Cell Transplantation(HSCT) for Genetic Diseases of Blood Cells
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03301168 -
Study of Gene Modified Donor T-cells Following TCR Alpha Beta Positive Depleted Stem Cell Transplant
|
Phase 1/Phase 2 | |
Terminated |
NCT02065869 -
Safety Study of Gene Modified Donor T-cells Following TCRαβ+ Depleted Stem Cell Transplant
|
Phase 1/Phase 2 | |
No longer available |
NCT01200017 -
Expanded Access Protocol (EAP) Using the CliniMACS® Device for Pediatric Haplocompatible Donor Stem Cell Transplant
|